Interpharm Total Current Assets from 2010 to 2025
| IPAH Stock | USD 0 0.00 0.00% |
Total Current Assets | First Reported 2010-12-31 | Previous Quarter 36.9 M | Current Value 26 M | Quarterly Volatility 4.3 M |
Check Interpharm Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Interpharm Holdings' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 9.1 M or Total Revenue of 56.6 M, as well as many indicators such as Price To Sales Ratio of 0.0105, Dividend Yield of 0.16 or PTB Ratio of 0.0696. Interpharm financial statements analysis is a perfect complement when working with Interpharm Holdings Valuation or Volatility modules.
Interpharm | Total Current Assets | Build AI portfolio with Interpharm Stock |
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Check out the analysis of Interpharm Holdings Correlation against competitors. For more detail on how to invest in Interpharm Stock please use our How to Invest in Interpharm Holdings guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Interpharm Holdings. If investors know Interpharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Interpharm Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.09) | Revenue Per Share | Quarterly Revenue Growth (0.07) | Return On Assets | Return On Equity |
The market value of Interpharm Holdings is measured differently than its book value, which is the value of Interpharm that is recorded on the company's balance sheet. Investors also form their own opinion of Interpharm Holdings' value that differs from its market value or its book value, called intrinsic value, which is Interpharm Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Interpharm Holdings' market value can be influenced by many factors that don't directly affect Interpharm Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Interpharm Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Interpharm Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Interpharm Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.